MEDVANCE 🔆

BUSINESS CASE

Market Access & Pricing support for a therapy for the treatment of rare genetic disorders of obesity in France, Spain, Italy and UK

Location Boston (US)	
Project aim access to the	project aim was to support the company in securing timely patient ne therapy at a price that is acceptable for both the company and s in 4 European countries (France, Spain, Italy, UK).
As a first state data was ca positioning envisaged in an optimal II A feedback company's of 	bine the draft European Market Access strategy ep, an in-depth analysis of the product environment and its available irrried out in each country (i.e., medical needs assessment, strategic in the current therapeutic management, target population of the dication, gap analysis, etc.). This study helped develop a strategy for European Market Access. meeting aligned Medvance's strategic recommendation with the objectives, allowing to select the best scenario to access the market. to underlined the most favourable conditions for access, through a approach in line with local regulations and each country's health p and submit reimbursement dossiers for each country assumed the responsibility for medical writing and led the nof each country's clinical dossier – with a designated clinical writer pecific sections. The company was closely involved in the review, omments on all draft versions. Medvance was also responsible for the ssion of the entire dossier to local regulatory authorities, and teractions with them during the assessment process. p and submit the economic dossier for each country wrote economic dossiers and adapted its approach according to each arket access specificity, developing for instance a conceptual health nodel, or conducting systematic literature reviews on the quality of economic evidence. rt the company in the price negotiation